Dietary Supplement Quality Agreement: What Brands and Contract Manufacturers Should Define
Date: 2026-09-20 Categories: Supplement Blog Hits: 280
Quick Answer
A dietary supplement quality agreement is a written operating map between a brand and its contract manufacturer. It assigns who approves specifications, qualifies materials, reviews tests, releases batches, controls changes, investigates complaints and retains records.
The agreement should be signed before commercial production, aligned with the supply contract and reviewed whenever the product, process, site or regulatory assumptions change. It can clarify responsibilities, but it does not eliminate either party’s obligations under applicable law.
What is a dietary supplement quality agreement?
A quality agreement converts broad promises such as “manufactured to specification” into named decisions, evidence and escalation routes. It answers three practical questions for every critical activity:
- Who performs the work?
- Who reviews or approves it?
- Which record proves that it happened?
This is different from a commercial supply agreement. The supply agreement normally governs pricing, payment, forecasts, liability and delivery. The quality agreement governs how product quality is defined, verified, documented and protected.
Quality agreement vs supply agreement vs product specification
| Document | Primary purpose | Typical owner | What it should not replace |
|---|---|---|---|
| Quality agreement | Assign quality responsibilities and evidence | Brand QA + manufacturer QA | Detailed specifications or commercial terms |
| Supply agreement | Set price, volume, delivery and legal terms | Commercial/legal teams | Quality procedures |
| Product specification | Define measurable acceptance criteria | Brand and technical teams | Responsibility mapping |
The three documents should reference one another without repeating conflicting language. If a specification changes, the related testing, label, packaging and release responsibilities should also be reviewed.
Ten sections the agreement should define
1. Product and document scope
List the covered products, dosage forms, markets, manufacturing sites and controlled documents. Define which version of each formula, specification, artwork and test method is current.
2. Ingredient and supplier controls
State who approves ingredient suppliers, who establishes identity specifications and how supplier changes are communicated. Clarify whether the brand may nominate a supplier and what happens if the proposed material does not meet agreed requirements.
3. Specifications and test methods
Identify who writes, reviews and approves specifications for components, in-process materials, finished product and packaging. Record which methods are used, how method changes are approved and how atypical or out-of-specification results are handled.
4. Manufacturing and packaging records
Define who creates master records, who reviews executed records and which deviations require brand notification. Include packaging reconciliation, label control and traceability expectations where relevant.
5. Batch disposition and release
Specify whether the manufacturer, the brand or both must approve a batch before shipment or market release. List the minimum release package and the turnaround expected after all required evidence is available.
6. Deviations, investigations and CAPA
Define severity levels, notification triggers and approval rights. A minor documentation correction should not follow the same escalation path as a confirmed specification failure or a potential consumer-safety event.
7. Change control
List the changes that require prior approval, advance notice or routine notification. Examples may include formula, supplier, test method, equipment, site, process, packaging, label or shelf-life changes.
8. Complaints, adverse events and recalls
Name the first receiver, investigation owner and decision authority. Include timelines for preserving samples, retrieving records, sharing findings and escalating potentially serious events.
9. Audits and record access
Set reasonable audit notice, frequency, confidentiality and follow-up rules. Define which records the brand can review, in what form and within what retrieval window.
10. Retention, termination and transition
State how long controlled records and samples are retained under the applicable requirements. Address access after the commercial relationship ends so a discontinued SKU does not become an evidence gap.
Responsibility matrix to complete before signing
| Activity | Brand | Manufacturer | Shared decision |
|---|---|---|---|
| Intended positioning and target market | Lead | Consult | Final scope |
| Formula and specification approval | Approve | Technical input | Controlled version |
| Component qualification | Define expectations | Execute agreed controls | Exceptions |
| Production and in-process control | Review agreed evidence | Lead | Critical deviation escalation |
| Finished-product testing | Approve plan | Execute or coordinate | Result interpretation |
| Batch release | Define market-release authority | Define shipment-release authority | Hold/reject decisions |
| Complaint investigation | Provide market evidence | Provide manufacturing evidence | Root cause and action |
| Change control | Assess market impact | Assess process impact | Approval route |
The exact allocation depends on the project. The important point is that no critical task is left as “assumed.”
A practical five-step setup process
- Map the product and markets. Confirm dosage form, claims, packaging and destination markets.
- List critical decisions. Start with specifications, testing, deviations, release, changes and complaints.
- Assign performer, reviewer and approver. Use job functions rather than individual names.
- Attach evidence requirements. Name the record, format, timing and retention rule.
- Run a scenario test. Walk through a failed result, urgent complaint and supplier change before signing.
B2B procurement checklist
Before approving the agreement, confirm that it:
- identifies every covered SKU and site;
- names the current specifications and controlled documents;
- separates shipment release from market release;
- defines deviation and complaint severity levels;
- gives clear change-notification triggers;
- states what evidence accompanies each batch;
- defines audit and record-access rights;
- addresses samples, complaints and recall support;
- survives termination for required record access;
- has no conflict with the supply agreement.
Frequently asked questions
Is a quality agreement the same as a manufacturing contract?
No. A manufacturing or supply contract focuses on commercial and legal terms. A quality agreement focuses on quality responsibilities, records, approvals and escalation.
Does signing a quality agreement transfer all responsibility to the manufacturer?
No. A contract can allocate tasks, but it does not erase legal responsibilities. Each party should obtain qualified regulatory and legal advice for its role and markets.
When should the agreement be signed?
Before commercial production begins and early enough to influence specifications, testing and release design. Waiting until the first shipment turns unresolved assumptions into delays.
Who should approve it?
At minimum, authorized quality representatives from both parties. Regulatory, operations, technical and legal teams may also need to review relevant sections.
Should every SKU have a separate agreement?
Not necessarily. One master agreement can cover multiple products if appendices clearly identify product-specific specifications, tests, records and exceptions.
What changes should trigger an update?
Any change that affects scope or responsibilities, including a new product, site, market, process, supplier, test method, packaging configuration or release model.
Should audit rights be unlimited?
They should be workable and risk-based. The agreement can define routine notice, emergency access, confidentiality, frequency and corrective-action follow-up.
What should a brand request with each batch?
The answer depends on the release model, but the agreement should name the exact certificate, test summary, deviation status and other approved evidence rather than saying “standard documents.”
Key takeaways
- A quality agreement is a responsibility and evidence map, not a marketing credential.
- It should align specifications, testing, release, changes, complaints and record access.
- Every critical task needs a performer, reviewer, approver and proof record.
- Scenario-testing the agreement exposes gaps before production starts.
- Brand-specific procedures and capabilities should be confirmed in writing before they are presented publicly.
Discuss Your Project
Planning a supplement project with multiple decision-makers? Send QUALITY with your dosage form, target market, expected launch window and current specification status. Aidacru can then confirm which project inputs are needed for a responsibility-mapping discussion; no capability is implied until confirmed in writing.
Editorial sources
- FDA dietary supplement CGMP overview: https://www.fda.gov/food/guidance-regulation-food-and-dietary-supplements/current-good-manufacturing-practices-cgmps-food-and-dietary-supplements
- FDA warning letter illustrating that a firm cannot contract away its CGMP responsibilities: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/evig-llc-dba-balance-nature-580888-08202019
Educational content only; not legal or regulatory advice.